Retreatment of recurrent adult medulloblastoma with radiotherapy: A case report and review of the literature

被引：8

作者：

Buglione M. ^{[1
]}

Triggiani L. ^{[1
]}

Grisanti S. ^{[2
]}

Liserre R. ^{[3
]}

Buttolo L. ^{[4
]}

Gipponi S. ^{[5
]}

Bonetti F. ^{[6
]}

Todeschini A. ^{[5
]}

Spiazzi L. ^{[7
]}

Magrini S.M. ^{[1
]}

机构：

[1] Radiation Oncology Department, Brescia University, 25123 Brescia

[2] Medical Oncology Department, Spedali Civili Hospital, Brescia, 25123 Brescia

[3] Neuroradiology Department, Brescia University, 25123 Brescia

[4] Neurosurgery Department, Brescia University, 25123 Brescia

[5] Neurology Department, Brescia University, 25123 Brescia

[6] Pathology Department, Brescia University, 25123 Brescia

[7] Physics Department, Spedali Civili Hospital, Brescia, 25123 Brescia

来源：

Journal of Medical Case Reports | / 7卷 / 1期

关键词：

Adult medulloblastoma; Biological equivalent dose; Re-irradiation;

D O I：

10.1186/1752-1947-7-64

中图分类号：

学科分类号：

摘要：

Introduction. Medulloblastoma, the most frequent brain tumor in childhood, also occurs with a wide range of characteristics in adult patients. Late relapse is common in adult medulloblastoma, and the overall survival of relapsed patients usually ranges from 12 to 15 months. Treatment at recurrence is still debated and after reoperation includes stereotactic or normofractionated radiotherapy, and high-dose chemotherapy with autologous bone marrow transplantation. Case presentation. We report on the case of a 31-year-old Caucasian woman who underwent re-irradiation for a recurrence of medulloblastoma at nine years after first irradiation (56Gy), focusing on the radiobiological background and a review of previous studies involving re-irradiation of recurrent medulloblastoma. After surgical excision of the relapsed tumor and medical multi-agent treatment, the site of recurrence was treated using three-dimensional conformal radiotherapy to a total dose of 52.8Gy (1.2Gy/fraction/twice daily). A total biological equivalent dose of 224.6Gy (α:β = 2 Gy) was delivered to the posterior fossa (first and second treatments). No radionecrosis or local recurrence was evident at 18 months after re-irradiation. Conclusion: Re-irradiation can be considered a possible and safe treatment in selected cases of recurrent medulloblastoma in adults. The reported radiobiological considerations could be useful in other cases involving re-irradiation of brain tumors. © 2013 Buglione et al; licensee BioMed Central Ltd.

引用

共 16 条

[1]

Chan A.W., Tarbell N.J., Black P.McL., Louis D.N., Frosch M.P., Ancukiewicz M., Chapman P., Loeffler J.S., Adult medulloblastoma: Prognostic factors and patterns of relapse, Neurosurgery, 47, 3, pp. 623-632, (2000)

[2]

Herrlinger U., Steinbrecher A., Rieger J., Hau P., Kortmann R.-D., Meyermann R., Schabet M., Bamberg M., Dichgans J., Bogdahn U., Weller M., Adult medulloblastoma: Prognostic factors and response to therapy at diagnosis and at relapse, Journal of Neurology, 252, 3, pp. 291-299, (2005)

[3]

Brandes A.A., Palmisano V., Monfardini S., Medulloblastoma in adults: Clinical characteristics and treatment, Cancer Treatment Reviews, 25, 1, pp. 3-12, (1999)

[4]

Kadota R.P., Mahoney D.H., Doyle J., Duerst R., Friedman H., Holmes E., Kun L., Zhou T., Pollack I.F., Dose intensive melphalan and cyclophosphamide with autologous hematopoietic stem cells for recurrent medulloblastoma or germinoma, Pediatr Blood Cancer, 51, pp. 675-678, (2008)

[5]

Poelen J., Bernsen H.J.J.A., Prick M.J.J., Metastatic medulloblastoma in an adult

[6]

treatment with temozolomide, Acta Neurologica Belgica, 107, 2, pp. 51-54, (2007)

[7]

Ruggiero A., Rizzo D., Attina G., Lazzareschi I., Mastrangelo S., Maurizi P., Migliorati R., Bertolini P., Pastore M., Colosimo C., Riccardi R., Phase i study of temozolomide combined with oral etoposide in children with recurrent or progressive medulloblastoma, Eur J Cancer, 46, pp. 2943-2949, (2010)

[8]

Patrice S.J., Tarbell N.J., Goumnerova L.C., Shrieve D.C., Black P.M., Loeffler J.S., Results of radiosurgery in the management of recurrent and residual medulloblastoma, Pediatr Neurosurg, 22, pp. 197-203, (1995)

[9]

Saran F., Baumert B.G., Creak A.L., Warrington A.P., Ashley S., Traish D., Brada M., Hypofractionated stereotactic radiotherapy in the management of recurrent or residual medulloblastoma/PNET, Pediatric Blood and Cancer, 50, 3, pp. 554-560, (2008)

[10]

Bakst R.L., Dunkel I.J., Gilheeney S., Khakoo Y., Becher O., Souweidane M.M., Wolden S.L., Reirradiation for recurrent medulloblastoma, Cancer, (2011)

← 1 2 →